Ullah Mutea, Arshad Junaid, Anwar Uzma, Khan Shehriyar, Amjad Anum, Zeb Arsalan, Majid Maham
Internal Medicine, University Hospital Birmingham, Birmingham, GBR.
Internal Medicine, Hayatabad Medical Complex, Peshawar, PAK.
Cureus. 2024 Nov 26;16(11):e74542. doi: 10.7759/cureus.74542. eCollection 2024 Nov.
Postmenopausal women are often affected by osteoporosis, a disorder that lowers bone density, increases the risk of fractures, and has a major negative influence on quality of life.
This study aimed to assess the efficacy of bisphosphonates in reducing fracture risk among postmenopausal women with osteoporosis by analyzing their impact across various fracture sites, treatment durations, and patient subgroups.
A retrospective cohort research was conducted between January 2021 and December 2022 at Hayatabad Medical Complex (HMC), Peshawar. Women 50 years of age and older who had been diagnosed with osteoporosis (BMD T-score < -2.5) and receiving bisphosphonates for at least a year were included in the research. We gathered information on treatment adherence, fracture history, and demographics. SPSS version 25 was used to conduct statistical studies, such as logistic regression and paired t-tests.
A total of 323 participants were included, with a mean age of 65.40 ± 8.20 years. The incidence of new fractures decreased significantly from 121 patients (37.48%) before therapy to 48 patients (14.85%) post-therapy (p < 0.0001), demonstrating the efficacy of bisphosphonates in fracture prevention. Notably, the most common fracture types were vertebral fractures in 49 patients (15.18%) and hip fractures in 42 patients (12.99%). Logistic regression analysis indicated that age (OR 1.05, 95% CI: 1.02 - 1.09) and baseline BMD T-score (OR 0.78, 95% CI: 0.67 - 0.90) were significantly associated with fracture risk reduction, highlighting the importance of these factors in treatment outcomes.
The significance of bisphosphonates in clinical therapy is highlighted by their ability to successfully lower fracture risk in postmenopausal women with osteoporosis.
绝经后女性常受骨质疏松症影响，该病症会降低骨密度，增加骨折风险，并对生活质量产生重大负面影响。
本研究旨在通过分析双膦酸盐在不同骨折部位、治疗时长和患者亚组中的影响，评估其在降低绝经后骨质疏松症女性骨折风险方面的疗效。
2021年1月至2022年12月在白沙瓦哈亚塔巴德医疗中心（HMC）进行了一项回顾性队列研究。研究纳入了年龄在50岁及以上、被诊断为骨质疏松症（骨密度T值＜-2.5）且接受双膦酸盐治疗至少一年的女性。我们收集了治疗依从性、骨折史和人口统计学信息。使用SPSS 25版进行统计分析，如逻辑回归和配对t检验。
共纳入323名参与者，平均年龄为65.40±8.20岁。新骨折发生率从治疗前的121例患者（37.48%）显著降至治疗后的48例患者（14.85%）（p＜0.0001），表明双膦酸盐在预防骨折方面的疗效。值得注意的是，最常见的骨折类型为椎体骨折49例（15.18%）和髋部骨折42例（12.99%）。逻辑回归分析表明，年龄（OR 1.05，95%CI：1.02 - 1.09）和基线骨密度T值（OR 0.78，95%CI：0.67 - 0.90）与骨折风险降低显著相关，突出了这些因素在治疗结果中的重要性。
双膦酸盐能够成功降低绝经后骨质疏松症女性的骨折风险，凸显了其在临床治疗中的重要性。
